Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-07-28
Schrödinger, Inc.
Schrödinger sells physics-based molecular discovery software and cloud workflows to pharma, biotech, industrial and academic customers and uses the same platform in collaborative and proprietary drug programs.
ai biotech cloud healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow ownership drives the upside
The main case is a business-model upgrade, not a single-asset drug bet. If hosted delivery, Bunsen and large-account expansion deepen recurring software value capture, the market can reward a cleaner science-software profile while collaborations remain additive upside.

Analysis

Thesis
Schrödinger’s 5-year upside comes from becoming a deeper, usage-led discovery operating layer inside pharma workflows: if hosted delivery, Bunsen and adjacent products raise paid throughput while clinical assets are partnered rather than self-funded, revenue quality and valuation can rerate without needing a single heroic drug outcome.
Last Economy Alignment
Cheaper cognition should increase simulation and design activity, and Schrödinger captures that through workflow integration and usage-led software. The risk is that general AI agents own the interface and compress Schrödinger into a back-end tool.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.1x (from 5 most recent analyses)
Reasoning
The bullish-but-grounded case is not that Schrödinger suddenly becomes a large biotech winner; it is that the company upgrades from a lumpy license vendor into a stickier discovery workflow system. Hosted contracts should make software revenue more recurring, Bunsen can widen paid utilization, and pharma embedment can support expansion into adjacent discovery steps. Drug discovery economics remain meaningful upside, but the main value driver is better software depth and better revenue quality.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The central risk is value capture, not scientific relevance. Schrödinger likely remains useful, but the upside narrows if hosted adoption does not improve software quality, if Bunsen fails to become a real paid workflow layer, or if concentration and clinical optionality stay too lumpy for investors to reward with a higher multiple.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.50
They sit inside drug-discovery workflows where better AI should drive more simulations, more decisions and more paid usage, and that can make the software harder to remove once teams build around it. The risk is that generic AI agents end up owning the interface and push Schrödinger into a cheaper back-end role.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$20.57
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case